Category Archives: Immunology

Experts present options to fully suppress COVID-19 while keeping the economy open – Newstalk

An immunologyexpert says Ireland can suppressthe coronavirus like New Zealand without further economic shutdowns.

It comes as more than 1,000 Irish scientists and doctors have warned that the country must completely eliminate COVID-19 before a return to normal life, with total suppression.

The widespread wearing of masks, faster testing and contact tracing, the testing of visitors at airport and a review the lockdown are all included to 'crush the curve'.

Dr Tomas Ryan is assistant professor at the school of biochemistry and immunology at Trinity College Dublin.

He told Pat Kenny: "I think we're certainly moving too fast, principally because our containment measures aren't in place.

"We are advocating for a scientific perspective in orientating our strategy for how we deal with COVID-19 in Ireland.

"But our motivation is to avoid lockdowns - what we want to do is avoid any further lockdowns so that we don't have more catastrophic economic consequences.

"Currently, we are on path for a second surge - and that second surge may happen in mid-summer or it may happen in the autumn.

"That will lead to another lockdown; and we won't have herd immunity in Ireland unless we suffer four to seven, or maybe more, of these lockdowns so that we can build up 65% infections in the population.

"That's what we want to avoid, and we think there's a better way of handling COVID-19 in Ireland."

He outlined two options, one of which is to suppress the virus as we have been doing.

"That would mean we would keep it like South Korea - we would live with virus but keep a flat curve, no new lockdowns until we have a vaccine.

"But the other option, which is what we're advocating for in this letter, is to go to where New Zealand has gone [and] eliminate the virus".

"There's an argument that we couldn't do this in March because we didn't have enough advance warning, but we have a second chance now - because our infection numbers are back to where they were at March 11th.

"If we keep going the way we're going, we're going to be back into mid-March - we're going to get there a little bit more slowly because of social distancing, but we'll face a second surge.

"Or we can choose to aim for what New Zealand did.

"This is where there's a number of different ways where we could implement this.

"Some people are quite right to say we could do this with a very sharp lockdown - and by sharp I mean slightly more rigorous than what we've experienced, and maybe only for four weeks."

"It could [also] be done by a hybrid approach of careful social distancing, localised lockdowns where necessary, masks and rigorous test-trace-isolate.

"So we don't need to shut down the economy, necessarily, to eliminate the virus - we certainly do need to watch travel into the country."

On the border issue, he said: "I think we could achieve at least the South Korean level of suppression without Northern Ireland cooperation.

"But... if we want to get to the New Zealand level of complete nonality, we really do probably need an all-Ireland approach.

"But I'm not too worried about that because I think that if we lead, I think that they will follow and I think it's a much better approach than going with what's been happening in Great Britain".

"This is our opportunity, it's the summer - we've got everything under control, we don't want to be in a situation where we arrive into September, it gets more difficult to manage because of winter, because of flu season and we ask ourselves why didn't we do this four months ago.

"We can make hay now and we should".

Experts present options to fully suppress COVID-19 while keeping the economy open

00:00:00 / 00:00:00

View post:
Experts present options to fully suppress COVID-19 while keeping the economy open - Newstalk

Bolt Biotherapeutics Announces Issuance of U.S. Patent for the Boltbody(TM) ISAC Technology and its Lead Development Candidate, BDC-1001 – Monterey…

REDWOOD CITY, Calif., June 9, 2020 /PRNewswire/ --Bolt Biotherapeutics, Inc., a private clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the immune system to treat cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,675,358 entitled "Antibody Adjuvant Conjugates." The patent provides protection for immunoconjugates of a piperazinyl imidazoquinoline adjuvant bound to any antibody, including Bolt's BDC-1001 ISAC embodiment.

BDC-1001 is being developed as a monotherapy for patients with HER2-expressing solid tumors. BDC-1001 is an ISAC comprised of trastuzumab conjugated to a Bolt proprietary TLR7/8 agonist payload.

Michael N. Alonso, Ph.D., scientific co-founder and vice president of immunology and pharmacology of Bolt, stated "The development of Boltbody ISACs is motivated by the insatiable need to translate scientific discoveries into products that will help cancer patients become survivors. This patent issuance is an important milestone that provides protection for our BDC-1001 clinical asset and our Boltbody ISAC technology platform. Our dedicated and talented teams will continue to aggressively build a robust patent portfolio to protect our pipeline, our platform, and our commitment to patients."

About Bolt Biotherapeutics' Immune-Stimulating Antibody Conjugate (ISAC) Platform Technology

The Boltbody platform consists of Immune-Stimulating Antibody Conjugates (ISAC) that harness the ability of innate immune agonists to convert cold tumors into immunologically hot tumors thereby illuminating tumors to the immune system and allowing them to be invaded by tumor killing cells. Boltbody ISACs have demonstrated the ability to eliminate tumors following systemic administration in preclinical models and have also led to the development of immunological memory, which is predicted to translate into more durable clinical responses for patients. The company's first Boltbody to enter clinical development, BDC-1001, is currently being evaluated in patients with HER2-expressing solid tumors.

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, based in the San Francisco Bay Area, is a private clinical-stage biotechnology company developing Boltbody Immune-stimulating Antibody Conjugates (ISACs), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt's platform technology is applicable to a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer, including patients who are refractory to the current generation of checkpoint inhibitors. The company was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit http://www.boltbio.com.

Media Contacts: Maggie Beller or David SchullRusso Partners, LLC646-942-5631maggie.beller@russopartnersllc.comdavid.schull@russopartnersllc.com

Investor Relations Contact: Sarah McCabeStern Investor Relations, Inc.212-362-1200sarah.mccabe@sternir.com

Original post:
Bolt Biotherapeutics Announces Issuance of U.S. Patent for the Boltbody(TM) ISAC Technology and its Lead Development Candidate, BDC-1001 - Monterey...

More Than One Way to Fix Cat Allergy – Medscape

There is new hope for cat lovers who are allergic to their pets. Rather than desensitizing the human, researchers are working to eliminate the Feld1 protein, the primary allergen, from the cat, using CRISPR-Cas9 gene-editing technology.

"One of the benefits of CRISPR, compared to other methods of tackling this problem, is that you can permanently remove Feld1, compared with other techniques that only reduce the allergen," said Nicole Brackett, PhD, from Indoor Biotechnologies.

Previous attempts to remove the allergen have included feeding cats a specially formulated food that reduces Feld1 in the saliva, so less ends up on the dander when they lick themselves, as reported by Medscape Medical News.

"We hope to get to a point where we can offer an injection, or a series of injections, you would get at the vet, which would make the cat allergen-free," said Brackett, who presented the research in a poster at the European Academy of Allergy and Clinical Immunology 2020 Digital Congress.

When you're using this kind of technology, you are taking on a tremendous amount of responsibility.

About 10% of humans are allergic to cats, and we see the ones who are affected by their own cats, said Dean Mitchell, MD, an allergist and immunologist from Mitchell Medical Group in New York City.

"This research is interesting, but when you're using this kind of technology, you are taking on a tremendous amount of responsibility," he told Medscape Medical News.

"It's really an exciting technology, but I think it's scary, altering genes," he said. "You never know what you're going to change. Maybe we should use it to cure COVID first."

For their study, Brackett and her colleagues used discarded tissue samples from 50 spayed and neutered cats to collect genomic DNA from the Feld1 chains1 and 2.

The first goal was to see how similar genes were between cats, she explained. "We wanted to target a region in the gene that is well conserved something you would see in all cats not a random mutation."

The researchers were able to sequence a panel of 10 guide RNAs and use CRISPR Cas-9 to edit the genes. "We now have proof of principle in a cat cell line," Brackett told Medscape Medical News.

We still have a long way to go, but should have something we can test in a cat in a couple of years. But, she acknowledged, "we still don't know the role of the protein in the cat."

Feld1 expression differs from cat to cat, Brackett pointed out. "Some cats have an abundance and some have very little. The expression can vary, even within one cat."

Speculation on the function of Feld1 also varies. Because it's produced in the sebaceous gland, "it may serve as a way to coat, or protect, the skin. Or maybe it has something to do with chemical communication, maybe to communicate with other cats," she said. "But the fact that we see so much Feld1 variability with no obvious correlating behaviors makes us think it's not essential. One of the benefits of our study is we may figure that out."

Her lab is also looking at Feld1 expression in wild cats to determine its origin from an evolutionary standpoint. "We are curious to see how this allergen has evolved in different species of cats," she explained.

Cat allergies "rank number two in frequency and seriousness of allergies after food allergies, causing people to need to be on steroids or medications," Mitchell told Medscape Medical News. "Fifty percent of my immunotherapy practice is cat or dog allergy; it's a significant problem."

Young kids can't play at their friend's houses, relationships are affected, and families have to choose between their beloved cat and a healthy family member, he said.

Sublingual immunotherapy of Feld1 has been proven effective in clinical trials and is common in Europe, but "only about 100 allergists in the United States offer it," Mitchell said. "It's been a very underappreciated therapy, and I really don't know why; maybe because it's not patentable by a drug company."

Sublingual drops are not covered by insurance, and the therapy runs about $120 per month in the United States. "I've helped hundreds of patients with it," said Mitchell, and usually the therapy significantly improves patient quality of life.

The fact is, people make major life choices based on their cats, Mitchell explained.

One of his pollen-allergic patients who loved both her cat and her cat-allergic boyfriend told him that her boyfriend wouldn't sleep over. "Can you help him?" she asked.

"The first day I see him, he's wheezing and can't breathe." Mitchell recalled. He treated the boyfriend with sublingual Feld1 immunotherapy. "After 4 or 5 months, he could go over to her house using inhalers on weekends sometimes. A year later, they moved in together and got married. The cat even slept on the bed at the end.

Mitchell discharged the boyfriend after 3 years of treatment. He ran into him on a New York sidewalk a couple of years later and asked how he was doing. It turned out the couple had gotten divorced.

"That's too bad, I told him. But at least you don't have to deal with the cat anymore," Mitchell recalled.

"Oh no, I liked the cat too much, he stayed with me," his patient told him.

Mitchell laughed. "You just can't make this stuff up!"

Brackett works for Indoor Biotechnologies as a scientist. Mitchell has disclosed no relevant financial relationships.

European Academy of Allergy and Clinical Immunology (EAACI) 2020 Digital Congress

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Read more:
More Than One Way to Fix Cat Allergy - Medscape

AstraZeneca’s Acquisition of Gilead Would Create a COVID-19 Colossus — but Don’t Bet on Seeing It Happen – Motley Fool

Nothing should be absolutely shocking in the biopharmaceutical world. But I'll admit, the reports that surfaced over the weekend thatAstraZeneca (NYSE:AZN) was interested in acquiringGilead Sciences (NASDAQ:GILD) were surprising.

Bloomberg recently reported that AstraZeneca had reached out to Gilead last month about a potential deal, according to the always-intriguing sources of "people familiar with the matter." Should this acquisition actually move forward, it would be the biggest healthcare deal ever -- and there have been plenty of really big takeovers in the healthcare sector over the last few years.

The combination of AstraZeneca and Gilead would create a COVID-19 colossus, considering that both companies have leading coronavirus programs. But don't bet on seeing this deal ever happen.

Image source: Getty Images.

AstraZeneca's market cap currently stands at around $140 billion, while Gilead's market cap is around $96 billion. The combination of the two big drugmakers would create the world's third largest healthcare company, behind only Johnson & Johnsonand UnitedHealth Group.

As previously mentioned, the merger of AstraZeneca and Gilead would also result in a formidable player in the COVID-19 arena. AstraZeneca partnered with the University of Oxford on developing a COVID-19 vaccine that was reportedly selected by the Trump administration as one of the five vaccines most likely to be successful and worthy of U.S. government support. Gilead's antiviral drug remdesivir appears to be headed toward becoming the standard of care for treating COVID-19.

The two companies would bring different strengths to the table. AstraZeneca claims three core franchises: oncology, CVRM (cardiovascular, renal, and metabolism), and respiratory and immunology. Gilead's current drugs focus primarily on HIV, hepatitis C, and oncology.

There's not any significant overlap right now between the two drugmakers' current lineups, though, despite both targeting oncology. AstraZeneca's top oncology products are targeted therapies Tagrisso and Lynparza and immunotherapy Lynparza, all of which treat solid tumors. Gilead's Yescarta is a CAR-T cell therapy targeting certain types of blood cancers.

Gilead hopes to soon enter the immunology market with FDA approval pending for filgotinib in treating rheumatoid arthritis. The biotech also is evaluating the drug in several other immunology indications. However, Gilead's immunology efforts shouldn't clash much with AstraZeneca's respiratory & immunology programs, which focus primarily on asthma and COPD.

While the fit between AstraZeneca and Gilead might seem pretty good, it's still very unlikely that the acquisition will actually happen. For one thing, Gilead reportedly wasn't interested. And after the initial inquiries by AstraZeneca, the pharma company's executives ultimately decided a deal wasn't worth pursuing, according to sources interviewed by British newspaper TheTimes.

Gilead doesn't need to be acquired. The company appears to be ready to return to solid growth after several years struggling with declining hepatitis C virus (HCV) franchise sales. Gilead's Biktarvy looks to be on track to become the biggest-selling HIV drug ever. Its HIV pipeline is impressive. The biotech also, as previously mentioned, has solid opportunities in COVID-19 and in immunology.

Meanwhile, AstraZeneca doesn't really need a big acquisition, either. The drugmaker continues to deliver solid growth thanks mainly to its strong oncology lineup. It also has a robust pipeline with 20 late-stage programs and over 50 life-cycle management (LCM) programs seeking additional indications for approved drugs.

There's also the matter of the size of any potential deal. AstraZeneca would almost certainly have to pay at least $130 billion (and probably more) to acquire Gilead. That large of an amount would require AstraZeneca to add a huge amount of debt since the company's cash position currently stands at around $4.2 billion.

The best bet for both AstraZeneca and Gilead is that both companies make smaller deals of their own, including both bolt-on acquisitions and collaborations.

Gilead has been much more active on this front over the last few years. The big biotech acquired Kite Pharma in 2017. More recently, it bought cancer-focused biotech Forty Seven for $4.9 billion earlier this year. Gilead also established a multi-year collaboration with Galapagoslast year with a price tage of $5.1 billion, including a $1.1 billion equity stake in the biotech.However, AstraZeneca's reported interest in Gilead could mean that the big drugmaker is ready to crank up its dealmaking.

My view is that AstraZeneca and Gilead are likely to strike a key deal in the not-too-distant future -- just not with each other.

More here:
AstraZeneca's Acquisition of Gilead Would Create a COVID-19 Colossus -- but Don't Bet on Seeing It Happen - Motley Fool

IsoPlexis Awarded $2 Million NIH Phase 2 SBIR Grant for Expanding Development of a Cellular Platform for Analyzing the Peripheral Immune Response in…

BRANFORD, Conn., June 9, 2020 /PRNewswire/ -- Isoplexis, the leader in functional single cell proteomics, announced today that it has been awarded a Phase 2 Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health for $2 million to continue analyzing the highly multiplexed proteomic responses of trafficking leukocytes in patients with Alzheimer's disease, neuroinflammation, and related neurodegenerative diseases.

The funds from this Phase 2 SBIR grant will be used by IsoPlexis to expand the development of a functional proteomic platform to determine effects of the inflammatory immune response on Alzheimer's progression. The IsoPlexis system will allow for the sensitive detection of responses from various immune cells such as peripheral monocytes, highly polyfunctional secretomic T cell types, and microglia, as biomarkers for early stage diagnosis and monitoring of inflammatory neurodegenerative diseases. This unique approach is non-invasive and should have broad impact and unique value for pre-clinical and clinical use.

"Immune-driven neuroinflammation is a significant contributor to the pathogenesis of diseases such as Alzheimer's. There is an urgent ongoing need for the accelerated development of novel therapeutics and diagnostics. We're excited to be developing solutions to better understand the functional mechanisms behind neuroinflammation," says Sean Mackay, CEO of IsoPlexis.

The IsoLight system is used globally by leading biotech, pharma, and academic medical centers to solve critical challenges in inflammatory diseases, infectious diseases, cell therapy, cancer immunology, and more.

IsoPlexis' functional cellular proteomics platform improves upon existing solutions by providing highly multiplexed, functional, secreted protein readouts, at the single-cell level and in very small sample volume bulk analysis, to advance detection of important drivers of immune system activity. IsoPlexis' technology has been used for precision drug discovery, as well as biomarker discovery in oncology, highlighting critical proteomic pathway changes that are often missed with traditional systems.

ABOUT ISOPLEXIS:

IsoPlexis (www.isoplexis.com) is dedicated to accelerating the fight against cancer and a range of the world's toughest diseases with its uniquely correlative, award-winning, cellular proteomics systems. By revealing unique immune biomarkers in small subsets of cells, we are advancing immunotherapies and targeted therapies to a more highly precise and personalized stage. Our integrated systems, named #1 innovation by the Scientist Magazine and Fierce, are used globally to advance the field of immune biology and biomarkers as we generate solutions to overcome the challenges of complex diseases.

ISOPLEXIS MEDIA CONTACT:

Jon ChenSenior Director of Marketinginfo@isoplexis.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/isoplexis-awarded-2-million-nih-phase-2-sbir-grant-for-expanding-development-of-a-cellular-platform-for-analyzing-the-peripheral-immune-response-in-alzheimers-disease-and-neuroinflammation-with-single-cell-proteomics-301072935.html

SOURCE IsoPlexis

Read the original post:
IsoPlexis Awarded $2 Million NIH Phase 2 SBIR Grant for Expanding Development of a Cellular Platform for Analyzing the Peripheral Immune Response in...

In Peoria, clinical trials and a new medicine are bringing hope to the sickest COVID-19 patients – News-Press Now

PEORIA -- Immunology researcher Dr. Joseph Kim switched his focus from organ rejection to COVID-19 in the last few months.

Since coming to Peoria in 2018, Kim had been working with OSF HealthCare Saint Francis Medical Center's organ transplant team to develop better treatments for organ rejection, but COVID-19 has brought him a new challenge.

As an infectious disease specialist, Kim is part of the team treating COVID-19 patients at St. Francis. As part of that work, he is gathering information for a clinical trial on a COVID-19 drug in development by I-Mab Biopharma. St. Francis is one of several hospitals across the country participating in the clinical trial to determine if the drug, currently known as TJ003234, is a safe and effective treatment for COVID-19. The drug is designed to treat the cytokine storm some patients suffer when their immune system overreacts to the virus.

"I'm sure you've heard in the news that some people have a lot of consequences from being sick with the virus: shock, acute respiratory distress, blood clots -- these are different things that happen after infection that may be related to the body's own response against the virus," said Kim. "So what's been shown is that people that have serious infection, their body's own immune response can be very dysregulated, it can be very exaggerated, and that can actually cause harm to the body."

TJ003234 works in a similar way as Tocilizumab, a more widely known drug already FDA approved to treat rheumatoid arthritis. Tocilizumab is also in clinical trials at other hospitals around the U.S. to test its efficacy for the treatment of COVID-19 patients. One of the things researchers are keeping a close eye on is side effects.

"If you are using something that's trying to counteract someone's immune response, some of the unintended consequences could be infection, because you obviously need your immune response to function well to fight off infection," said Kim. "So that's a big concern. So that's why these things need to be studied, obviously."

Clinical trials like this are happening all over the world in the race to come up with an effective treatment for COVID-19. Hospitals are enrolling in trials not only to help researchers, but also to be able to provide some hope for patients and their families for a virus that currently has no known treatments.

"So that's what we've been focusing on at OSF, getting in trials that allow us to give treatments to patients that are very, very sick that wouldn't be available otherwise," said Kim.

The trial, which began in mid-April, is in an early stage, where just a few patients have been given the drug to make sure it is safe, said Kim. Once safety is determined, it will be administered to more patients, and results will be recorded to determine if it is helping. Since it is a double-blind trial, with one group getting the drug and another getting a placebo, Kim and other researchers won't know the results until all the data is gathered.

The clinical trial is one of two COVID-19 trials being done at St. Francis. It is also participating in a clinical trial headed by Mayo Clinic on convalescent plasma, anti-body rich blood plasma gathered from recovered COVID-19 patients.

"Your body makes antibodies, and those antibodies can be protective against that virus," said Kim. "So basically what you are trying to do is taking the antibodies that are protective and give them to someone who doesn't have them yet, someone whose body is not making effective antibodies."

The convalescent plasma study is not a blind study, and last month researchers announced that a couple patients who had received the plasma were recovering. But as yet, those happy results are only anecdotal -- researchers are not yet ready to say if convalescent plasma is truly helpful in the treatment of COVID-19.

"With all these studies, you can't draw firm conclusions with such a small sample size and one physician's experience with a patient," said Kim. "That's the problem, and that's what's so hard about being able to treat patients and navigate through this pandemic -- we don't have this type of data yet. For other infections, like influenza, we have different treatments and vaccines. Influenza has definitely been studied well, so we can be confident about the effectiveness of what we are doing. It's just unfortunate that it's just not like that for COVID-19."

Another treatment doctors at St. Francis are using is Remdesevir. Because it has already been studied and has shown enough promise that the FDA gave it emergency-use approval, hospitals don't have to enroll in a clinical trial to get the drug.

"We've used it in Peoria on three patients so far," said infectious disease specialist Dr. Douglas Kasper, a faculty member at the University of Illinois College of Medicine Peoria. "Remdesevir can be used as an antiviral agent, with the idea that you are arresting viral replication as early as possible."

Though it has shown some promise in one study, doctors are still evaluating its worth as a treatment, said Kasper. Another issue with Remdesevir is that it is in very short supply. Area hospitals have only been given enough to treat a few patients.

All research is contingent on need, and no one knows what the need will be for COVID-19 treatments going forward.

"To do a clinical trial, you have to have sick people, otherwise you don't have anyone to enroll in the trial," said Kasper. "As the summer goes, and if our rates continue to go down, we won't make progress because we won't have anyone to enroll. That is kind of what happened with the first SARS virus. It was circulating mostly in Asia, causing terrible effects, and there was a huge response into the development of therapeutics and a vaccine. Towards the end of that outbreak, the virus mutated and became weaker, and clinical effects on people were less -- people didn't go to hospital and didn't die, then drive from industry became less. Could that happen with COVID-19? It could, but it's not something you could bet on. We don't know. That's the part of this that is so interesting -- each day, every week, it changes so much. To be able to match all this up and plan is quite a process."

Continue reading here:
In Peoria, clinical trials and a new medicine are bringing hope to the sickest COVID-19 patients - News-Press Now

Are we underestimating how many people are resistant to Covid-19? – The Guardian

During the first wave of the Covid-19 pandemic, cities were in general affected worse than smaller conurbations or rural areas. Yet in Italy, Rome was relatively spared while the villages of Lombardy experienced very high rates of sickness and death. Then again, one Lombard village Ferrara Erbognone stood out for not recording a single case of Covid-19 at the height of the wave. Nobody knows why.

The puzzle is not just Italian. From the beginning, Covid-19 struck unevenly across the globe, and scientists have been trying to understand the reasons. Why are some populations or sectors of a population more vulnerable than others? Or to turn the question around, why are some groups relatively protected?

In the Observer last weekend, neuroscientist and Covid-19 modeller Karl Friston of University College London suggested on the basis of his comparison of German and British data that the relatively low fatality rates recorded in Germany were due to unknown protective factors at play. This is like dark matter in the universe: we cant see it, but we know it must be there to account for what we can see, he said.

While this is a novel view most experts praise Germanys lockdown and systematic testing regime others are working hard to identify factors which are modulating the spread of Covid-19 and in doing so could explain other puzzles such as why Japan seems to have avoided a lethal first wave despite its relatively old population and lacklustre public health response, or why Denmark, Austria and the Czech Republic have reported no surge in cases despite their early easing of lockdown measures. That could shape how governments manage the risks of a second wave.

One thing seems clear: there are many reasons why one population is more protected than another. Theoretical epidemiologist Sunetra Gupta of the University of Oxford thinks that a key one is immunity that was built up prior to this pandemic. Its been my hunch for a very long time that there is a lot of cross-protection from severe disease and death conferred by other circulating, related bugs, she says. Though that cross-protection may not protect a person from infection in the first place, it could ensure they only experience relatively mild symptoms.

Guptas hunch has remained just that, because of the lack of data on immunity to Covid-19. Antibody testing, as we know, was slow to get going and unreliable to begin with, and the results to date suggest that the proportions of populations carrying antibodies to the Covid-19 virus are often in single or low-double digits. New, more sensitive antibody tests that have become available in recent weeks could soon provide a much more accurate picture if deployed widely enough, but there are already hints that the results to date may be underestimates.

First there was evidence based on diagnostic testing of postmortem samples from patients who died in December that the virus was circulating in western countries notably France and the US about a month earlier than was initially thought. New research shows that another component of the human immune response T cells, which help orchestrate the antibody response show memory for coronavirus infection when exposed to Sars-CoV-2, the virus that causes Covid-19.

In a paper published in Cell on 14 May, researchers at the La Jolla Institute for Immunology in California reported that T cells in blood drawn from people between 2015 and 2018 recognised and reacted to fragments of the Sars-CoV-2 virus. These people could not have possibly seen Sars-CoV-2, says one of the papers senior authors, Alessandro Sette. The most reasonable hypothesis is that this reactivity is really cross-reactivity with the cousins of Sars-CoV-2 the common cold coronaviruses which circulate very broadly and generally give rather mild disease.

The finding supported an earlier one from a group at the Charit hospital in Berlin, detecting T cell reactivity to proteins in the Sars-CoV-2 virus in 83% of Covid-19 patients but also in 34% of healthy volunteers who had tested negative for the virus itself.

David Heymann, an epidemiologist at the London School of Hygiene and Tropical Medicine who advises the World Health Organization on Covid-19, says these results are important, but cautions that cross-reactivity doesnt necessarily translate into immunity. To determine whether it does would involve following a large number of people who show such cross-reactivity to see if they are protected, if not from infection with Covid-19, then at least from severe forms of the disease.

It is, however, a reasonable hypothesis that exposure to other coronaviruses could confer protection, Sette says. Weve seen it before, for example with the 2009 H1N1 flu. Older people fared well compared to other age groups in that pandemic, he says, probably because their immune systems had been primed by exposure to similar flu strains from decades before. That could be the reason the 2009 pandemic was less lethal than other flu pandemics in history, killing an estimated 200,000 people globally.

If exposure to other coronaviruses does protect against Covid-19, Gupta says, then variability in that exposure could explain much of the difference in fatality rates between countries or regions. Exposure to the related virus that caused the epidemic of severe acute respiratory syndrome (Sars) in 2002-4 might have afforded some protection to east Asians against Covid-19, for example.

In late March, Guptas group published a paper that drew attention because it generated very different forecasts from those of epidemiologist Neil Ferguson of Imperial College London and his colleagues to whom the UK government was listening most closely. The Oxford group suggested that up to half of the UK population could already have been infected by Sars-CoV-2, meaning the infection fatality rate (IFR) the proportion of infected people who went on to die was much lower than Fergusons group was indicating, and the disease was therefore less dangerous. Neither group had much data at that point, and Gupta says that her intention was to highlight that, in the absence of data, a wide range of scenarios should be considered.

Two months on, she stands by her model, but wishes that she had made its implications clearer. The truth is that the IFR is not a hardwired property of the virus or of our interaction with the virus, she says. Its the vulnerable fraction [of the population] that is determining the average overall risk of dying. Once an elderly care home is infiltrated by the virus, for example, the virus spreads rapidly through it and is often lethal, pushing up the IFR. This means it is critical to understand why some people are resistant and others are not, so that those who are vulnerable can be protected.

We know some of those vulnerability factors. Age is the most obvious one. Unlike with the 2009 flu, elderly people are particularly vulnerable to Covid-19 a fact that might reflect the history of exposure to coronaviruses of different age cohorts. Comorbidity is another, and a third is being male. According to Garima Sharma of Johns Hopkins University School of Medicine in Baltimore, who with colleagues recently published a paper on sex differences in Covid-19 mortality, women are protected by virtue of having a backup X chromosome. X chromosomes contain a high density of immune-related genes, so women generally mount stronger immune responses, she says.

Socioeconomic status, climate, culture and genetic makeup could also shape vulnerability, as could certain childhood vaccines and vitamin D levels. And all of these factors can vary between countries. The Japanese might have been afforded some protection, for example, by their custom of bowing rather than shaking hands. And though most of the disparity between the sexes is down to biology, Sharma says some of it is due to social and behavioural factors, with women being more likely to wash their hands and seek preventive care.

It is also becoming clear that protecting the vulnerable has made a big difference to outcomes so far. Italy and Germany, for example, have similar proportions of over-65-year-olds just over 20% of the population in both cases and yet the two have reported strikingly different fatality rates. The case fatality rate (CFR) the proportion of the sick who go on to die is less informative but easier to measure than the IFR, because sick people are more visible than merely infected ones, and as at 26 May the CFR in Italy was about 14%, compared to 5% in Germany.

Italy is more densely populated than Germany, and Italian homes tend to be smaller than German ones. Many Italians in their 20s and 30s live at home with their extended families, which meant that transmission to the elderly was high and, when critical care units were overwhelmed, so were deaths. This is rarer in Germany, where many elderly care homes also enacted a strict isolation regime. In Germany, says Heymann, they did a better job in keeping the elderly protected. Some estimates suggest that only 20% of German Covid-19 cases were over 60, as compared to more than 90% in Italy.

The UK, which has recorded the second highest death rate from Covid-19 after Spain, has not looked after its elderly so well deciding at one point to discharge patients from hospitals back to care homes without testing them for the disease. The governments advice to 1.5 million UK citizens with underlying health conditions to self-isolate for three months from late March may have helped protect those people, but for Gupta the UKs high death rate reflects a deeper problem years of erosion of community support services that provided pastoral care. There is just not enough investment in the NHS and in that GP or other frontline individual who advises the vulnerable person, she says.

Holding to her hunch, she believes that lockdown was an overreaction and that frontline care and protection of the vulnerable which should have been a priority from the beginning should be prioritised now. She also thinks that the worst is behind us, and that while subsequent waves cant be ruled out, they will probably be less bad than what we have experienced so far. The disease will settle into an endemic equilibrium, in her view, perhaps returning each winter like a seasonal flu.

Fristons models also suggest that immunity in the population is higher than data indicates, but for him its not clear how long that immunity will last and he argues that test-and-trace protocols should be put in place now, ahead of any possible second wave that might erupt once that immunity drops off. Heymann remains wary of models, which he says have too often been mistaken for reality in this pandemic, and he awaits more data: I dont think anybody can predict the destiny of this virus at this point in time, he says.

Continue reading here:
Are we underestimating how many people are resistant to Covid-19? - The Guardian

Biomarkers of Exacerbation in Severe Asthma – Pulmonology Advisor

High counts of blood eosinophils combined with increased fractional exhaled nitric oxide (FeNO) may serve as biomarkers for a risk for exacerbations in patients with severe asthma, according to study results published in the Journal of Allergy and Clinical Immunology: In Practice.

With this 52-week, prospective, single-arm, longitudinal, noninterventional, multicenter ARIETTA study (ClinicalTrials.gov identifier: NCT02537691) conducted in real-world patients with severe asthma, investigators sought to evaluate the ability of type 2 biomarkers to predict severe outcomes. The primary study endpoint was the asthma exacerbation rate over 52 weeks in serum periostin-high (50 ng/mL at baseline) vs serum periostin-low (<50 ng/mL at baseline) subgroups.

The total number of exacerbations observed over 52 weeks divided by the total patient-weeks was used to estimate the unadjusted exacerbation rate. Secondary study outcomes were: the percentage of patients with treatment failure; the percentage of participants with changes in standard-of care treatments that were considered to be clinically meaningful; the time to initial asthma exacerbation; the time to treatment failure; the change from baseline in FeNO levels; the change from baseline in prebronchodilator forced expiratory volume in 1 second (FEV1); the change from baseline in patient-reported quality of life; and safety over 52 weeks in periostin-high and -low subgroups.

A total of 465 adult patients (median patient age, 54 years; range, 17-83 years; 66.5% women) from 84 sites in 13 countries with severe asthma were enrolled. Participants were receiving daily inhaled corticosteroids (fluticasone propionate 500 g or equivalent) and 1 second controller medication. Biomarker, clinical, and safety data were collected from all of the participants over 52 weeks.

The median time since a diagnosis of asthma was 19.4 years. In the prior year, 42.4% of patients had experienced 1 asthma exacerbation. At baseline, 52.0% of patients were periostin-high and 48.0% of participants were periostin-low. Overall, 87.5% of participants had type 2 inflammation (ie, blood eosinophils 150 cells/L and/or FeNO 25 ppb, and/or positive skin allergen test).

Biomarker levels were found to correlate poorly with each other. Central and local laboratory blood eosinophil and immunoglobulin E measurements, however, were generally in agreement. There was no significant difference reported in asthma exacerbation rates over 52 weeks between periostin-high and periostin-low subgroups (rate ratio, 0.93; 95% CI, 0.67 to 1.28; P =.642). Higher exacerbation rates were observed in participants with blood eosinophils 300 cells/L and FeNO 25 ppb.

[T]here were no clinically meaningful differences in the exacerbation rates between periostin-high and periostin-low subpopulations of patients with severe asthma in this study. Key Type 2 biomarkers, including periostin, blood eosinophils, serum IgE, and FeNO, were not highly correlated with each other, concluded the study authors. [P]ost hoc exploratory analyses suggested a potential clinically relevant predictive and prognostic ability for asthma exacerbation of blood eosinophils and FeNO when used in combination.

Reference

Buhl R, Korn S, Menzies-Gow A, et al. Prospective, single-arm, longitudinal study of biomarkers in real-world patients with severe asthma [published online April 15, 2020]. J Allergy Clin Immunol Pract. pii: S2213-2198(20)30338-X. doi: 10.1016/j.jaip.2020.03.038

Read the rest here:
Biomarkers of Exacerbation in Severe Asthma - Pulmonology Advisor

Covid-19: ‘We have to assume the virus has attenuated’ – RNZ

Covid-19 has likely become less potent as it mutates over time, and hopefully one day will become a common cold virus, a New Zealand, London-based professor says.

Photo: Unsplash / Kvin et Laurianne Langlais

Professor Alberto Zangrillo, head of intensive care at Italy's San Raffaele Hospital in Lombardy, says the new coronavirus is losing its potency and has become much less lethal. He told state television the new coronavirus "clinically no longer exists".

But World Health Organisation experts and a range of other scientists said there was no evidence to support his claim.

There is no data to show the new coronavirus is changing significantly, either in its form of transmission or in the severity of the disease it causes, they said.

But New Zealander Gary McLean, a professor in molecular immunology at London Metropolitan University, told Sunday Morning he was inclined to believe Zangrillo, whose claim was backed up by a second doctor from northern Italy who said he was also seeing the coronavirus weaken.

"They've experienced the full gamut of this virus and the effects and I think we have to believe what they're saying, the clinical picture that is. If they're seeing reduced severity there must be something to it.

"It's really difficult to know why exactly at this point, because there's a lot of reasons why it could be and there's no scientific literature, peer-reviewed papers that really document this, but if the clinicians are saying that I have to think it's probably real."

The virus may well have changed or attenuated causing a change in the clinical picture, McLean said.

"I would probably favour that in some way the virus is attenuating itself, just by accumulating mutations over timeand these little mutations accumulate and eventually the virus has had long enough in that host, in humans, it will drift and change slightly," McLean said.

Zangrillo, well known in Italy as the personal doctor of former Prime Minister Silvio Berlusconi, said his comments were backed up by a study conducted by a fellow scientist, Massimo Clementi, which Zangrillo said would be published soon.

Zangrillo said: "We have never said that the virus has changed, we said that the interaction between the virus and the host has definitely changed."

He said this could be due either to different characteristics of the virus, which he said they had not yet identified, or different characteristics in those infected.

The study by Clementi, who is director of the microbiology and virology laboratory of San Raffaele, compared virus samples from Covid-19 patients at the Milan-based hospital in March with samples from patients with the disease in May.

"The result was unambiguous: an extremely significant difference between the viral load of patients admitted in March compared to" those admitted last month, Zangrillo said.

Oscar MacLean of the University of Glasgow's Centre for Virus Research said suggestions that the virus was weakening were "not supported by anything in the scientific literature and also seem fairly implausible on genetic grounds."

Experts and representatives of Johns Hopkins University, Wake Forest Baptist Medical Center, George Washington University and Northwell Health also said they were not aware of evidence suggesting that the virus had changed.

Could Covid-19 become a common cold?

Gary McLean said there were 40 known coronaviruses, including seven which have infected humans, including four which are endemic cold viruses which cause relatively mild symptoms.

"One could argue originally those four might have been similar to SARS1, MERS and SARS2, and they attenuated themselves and became just a mild common cold."

One of the endemic strains, OC43, has been mapped back in time and the common ancestor is a cow coronavirus thought to have jumped into humans in 1890, McLean said.

"And coincidentally in 1890 there was a world-wide pandemic of a respiratory disease that killed one million people. And you can put one and one together and assume OC43 may have come from a pandemic and over the next 130 years it's evolved into a very mild, common cold virus," McLean said.

"And I'm hoping it doesn't take 130 years for this one to get that mild, but let's say it might take a year or so and we're going to have another common cold coronavirus.

"So I'd like to predict that but I don't know for sure if that will happen."

- Reuters/ RNZ

Continued here:
Covid-19: 'We have to assume the virus has attenuated' - RNZ

Immunology- An Overview of Immune System, its Types, Disorders

ImmunologyDefinition

The study of the immune system, the cell-mediated and humoral aspects of immunity and immune responses.

Immunology is a branch of the biology involved with the study of the immune system,components of the immune system, its biological process,the physiological functioning of the immune system, types, its disorder and lot more.

The immune system acts as a bodys defence system by protecting our body cells, tissues and organs from invading infection through various lines of defence. Overall,the immune system functions as a physical barrier and avoid the entry of pathogens including theharmful microorganisms and other disease-causing microbes.

Under certain conditions, when ourimmune system stops functioning, then this results in infectious diseases, such as allergies, fever, flu, and may also lead to a dreadful disease like cancer and etc.

Also Read: Immunity

Let us have a detailed look at Immunology to learn about the immune system, its different parts, functions and other significances of Immunology.

Immune System consists of different types of cells and molecules which protect our body against pathogens.Pathogens are defined as everything from parasites to fungi, bacteria, viruses, and haptens. Haptens are molecules that may cause an immune response when comes in contact with a protein. All these cells and molecules are distributed in all the tissues of the body as well as lymphoid organs which eliminate or prevent microbial infectious diseases to decrease the growth of tumours and starts the repairing process of damaged tissues.

The tissues and organs of the immune system act as security forces where cells act as the security guards while molecules act as the guns & bullets and use the communication system to protect you.

We, humans, havetwo typesof Immune System and are classified based on itsresistance power against theinfectious agents.

Immune System fights against microbes.

Innate Immune System is composed of cells and proteins that are present and always ready to fight against microbes in the infection area. InnateImmune System is present from the time of our birth.

Main elements of the innate immune system are

The Adaptive Immune System is required to fight against pathogens that can control innate immune defences. It is also referred to as the Acquired Immune System because it is acquired during the course of life.

All the components of the adaptive immune system are generally inactive however when activated; these components adjust to the presence of all the infectious agents by proliferating and developing a potent mechanism for eliminating the microbes.

Two Types of adaptive responses are humoral immunity moderated by antibodies which are developed by B lymphocytes and cell-mediated immunity, moderated by T Lymphocytes.

Normally, the diseaseoccurs because of fundamental defects in the immune system. In this situation, the immune system is challenged and evoke responses that damage cells and tissues rather than protecting. All the immunodeficiency diseases increase the risk of tumours and infections and are caused by malnutrition, gene mutations, and viruses HIV.

Also Refer:Antigens and Immunology

This is an experimental method used for studying the structure and functions of the immune system. There are differenttechniques, which includes:

Immunology is widely used in numerousdisciplines, including inmedicine, in the fields of organ transplantation, bacteriology, oncology, virology, parasitology, Rheumatic diseases, psychiatric disorders, and dermatology. TheImmunology of transplantation mainly deals with the process oftransplantationfrom a donor to the recipient.

This was a brief introduction toImmunology, for more information onImmunology, immune system, itstechniques, notes forImmunology class 12, visit us at Byjus Biology.

See the article here:
Immunology- An Overview of Immune System, its Types, Disorders